Phase 3 Stroke Trial, Recruiting NCT06129175 Sponsor: Cytopeutics Sdn. Bhd. Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06129175
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 years or older
  • People who had a stroke caused by a blocked blood vessel, with symptoms starting within the last 4 weeks
  • People whose stroke has been rated as "moderate to severe" using a standard medical stroke scale (a score of 6–24 on the NIHSS) at the time of joining the trial
  • People who are not eligible for clot-busting medication or a procedure to remove the clot
  • People (or their next-of-kin) who are able to provide written consent to take part

Who may not be able to join:

  • People who are medically unstable, such as those with unstable heart or blood pressure, or whose overall health condition is getting worse
  • People whose stroke was a "mini-stroke" (also called a TIA), where symptoms went away on their own
  • People who have been diagnosed with cancer (past or present) or a blood disorder
  • People with significant kidney problems, based on specific blood test results (confirm with trial site)
  • People with significant liver problems, based on specific blood test results showing liver enzyme levels more than twice the normal range (confirm with trial site)
  • People who are pregnant or breastfeeding
  • People whose brain scans show a bleed in the brain, a tumour, an abscess, abnormal blood vessels, severe brain shrinkage, or other non-stroke brain conditions
  • People who have been diagnosed with, or are suspected of having, a serious heart condition involving blocked heart arteries (acute coronary syndrome)
  • People with heart failure
  • People with a history of confirmed or suspected blood clots in the lungs (pulmonary embolism) or a chronic lung condition called COPD
  • People with mental health, thinking, or psychological difficulties that may affect their ability to understand the study or attend follow-up appointments
  • People who are currently taking part in another clinical trial, or who have taken part in one in the past 3 months

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Wan Nur Nafisah Wan Yahya, National University of Malaysia

Phone: +603-8688 1098

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Cytopeutics Sdn. Bhd.
Registry
ClinicalTrials.gov
Start date
19 December 2023
Est. completion
30 November 2026

Where this trial is recruiting

🇲🇾 Malaysia

Primary endpoints

Barthel Index (BI); Modified Rankin Scale

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov